Sutro Biopharma (STRO) has disclosed a new risk, in the Capital Markets category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sutro Biopharma may face heightened supply chain and operational risks as evolving U.S.-China trade tensions introduce uncertainty around tariffs, data exchange rules and cross-border flows of components and information. Any escalation, retaliatory measures or renegotiated trade agreements could materially impact its clinical development timelines, cost structure, financial performance and cash flows.
Overall, Wall Street has a Moderate Buy consensus rating on STRO stock based on 4 Buys and 1 Sell.
To learn more about Sutro Biopharma’s risk factors, click here.